Preventing Low-Value Care in Lifestyle Medicine in Viet Nam: Unnecessary Testing, Unsupported Interventions, and Patient Safety

EVIDENCE & CLINICAL PRACTICERESEARCH & IMPLEMENTATION

11/22/202628 min read

Preventing Low-Value Care in Lifestyle Medicine in Viet Nam: Unnecessary Testing, Unsupported Interventions, and Patient Safety

Last reviewed: November 22, 2026

A person who feels generally well visits a healthcare facility hoping to understand how to improve their long-term health. During the consultation, they are offered an extensive laboratory package measuring dozens of biomarkers, together with additional investigations intended to identify nutritional deficiencies, metabolic abnormalities and potential future health risks.

When the results arrive, several values fall outside the laboratory reference ranges. The patient becomes concerned and is advised to undergo further testing, take supplements and follow a restrictive dietary program. Yet important questions remain unanswered. Were the original investigations clinically indicated? Do the abnormal results represent meaningful disease? Will the proposed interventions improve health, or might they introduce additional costs and risks without sufficient benefit?

This situation illustrates a growing challenge for preventive healthcare and Lifestyle Medicine.

Advances in laboratory technology, digital monitoring and personalized health services have made it easier to collect information about the human body. At the same time, interest in prevention, longevity and health optimization has expanded the range of investigations and interventions available to people who may have few symptoms or no established medical condition.

Some of these developments offer genuine clinical value. Others generate findings that are difficult to interpret or lead to interventions whose benefits have not been adequately demonstrated.

More information, more testing and more treatment do not necessarily mean better healthcare.

Lifestyle Medicine is grounded in evidence-based interventions involving nutrition, physical activity, restorative sleep, stress management, positive social relationships and avoidance of harmful substances. Its credibility depends on applying these interventions appropriately, as part of responsible clinical care.

It should not become another justification for unnecessary investigations, unsupported treatments or expensive health optimization packages presented as essential to prevention.

For Viet Nam, the issue deserves attention as interest grows in preventive health services, comprehensive metabolic assessments, personalized nutrition and other approaches marketed around long-term well-being.

The objective is not to discourage prevention, early diagnosis or appropriate treatment. It is to ensure that investigations and interventions have a clear clinical purpose, a sound evidentiary foundation and an acceptable balance of expected benefits, potential harms and burdens for the individual patient.

Understanding Low-Value Care

Low-value care generally refers to healthcare services that offer little or no meaningful benefit in a particular clinical context, especially when their potential harms, burdens or costs outweigh the expected advantages.

The concept extends beyond treatments that are clearly ineffective. A laboratory test may be technically accurate but contribute little to patient care if its result is unlikely to change management. A treatment may be effective for one medical condition but inappropriate when offered to someone without a relevant indication. A screening intervention may detect additional abnormalities without demonstrating that earlier identification improves outcomes that matter to patients.

Low-value care is therefore context-dependent. The same investigation may be essential for a person with relevant symptoms or risk factors and unnecessary when routinely included in a broad screening package for someone unlikely to benefit.

Several related concepts help explain the problem.

Overuse refers to healthcare services provided when their expected benefits are insufficient to justify their use. Overdiagnosis occurs when a person is correctly identified as having a condition that would not have caused symptoms or harm during their lifetime. This differs from a false-positive result, in which an investigation incorrectly suggests that a condition is present.

Overtreatment occurs when an intervention is unnecessary or more intensive than the patient's clinical circumstances justify.

These problems may overlap, but they are not interchangeable. A false-positive result can lead to further investigations before clinicians establish that the suspected disease is absent. Overdiagnosis may lead to treatment of a genuine finding that would never have caused harm. Overtreatment can occur even when the diagnosis is appropriate but the intervention provides insufficient additional benefit.

Understanding these distinctions helps healthcare professionals identify where unnecessary care originates and how it might be prevented.

Reducing low-value care should never be confused with withholding necessary services. Avoiding unnecessary investigations is beneficial only when patients continue to receive appropriate screening, timely diagnosis and effective treatment.

What Recent Research Shows About General Health Checks

General health checks are often promoted as an essential part of preventive healthcare. They may combine medical history, physical examination, laboratory investigations and other assessments intended to identify disease or risk factors before symptoms develop.

However, their effectiveness depends on the population being assessed, the investigations included and whether detecting an abnormality leads to an intervention that improves meaningful outcomes.

A systematic review published in BMC Public Health on July 8, 2026, examined the effectiveness and cost-effectiveness of general health checks in adults.[1]

The review included 74 articles representing 56 independent studies and more than 17 million participants. The evidence comprised 22 randomized controlled trials, five nonrandomized controlled trials, 25 observational studies, three economic evaluations and one mixed-methods study.

Randomized trials generally did not demonstrate statistically significant reductions in all-cause mortality or cardiovascular events compared with usual care.

Some studies nevertheless reported greater detection of chronic conditions, increased use of preventive services and modest improvements in selected health behaviors or patient-reported outcomes.

The distinction is important. Detecting more abnormalities is not necessarily equivalent to preventing more illness or death.

Earlier identification can be beneficial when an effective intervention is available and the balance of benefits and harms is favorable. However, additional diagnoses may also generate unnecessary follow-up, anxiety and treatment when the detected abnormalities are unlikely to affect health.

The review identified uncertainty about long-term cost-effectiveness. Although some studies reported favorable short-term economic outcomes, results varied considerably across settings and methods.

A Cochrane systematic review published in 2019 reached a broadly consistent conclusion regarding general health checks offered to adults without specific clinical indications.[2]

The review included 17 randomized trials, with 15 reporting outcome data from 251,891 participants.

General health checks had little or no effect on all-cause mortality or cancer mortality, supported by high-certainty evidence. They also probably had little or no effect on cardiovascular mortality, supported by moderate-certainty evidence.

These findings should not be interpreted as an argument against preventive healthcare.

The reviews examined broad health-checking approaches, not every evidence-based screening intervention. They do not establish that clinically indicated investigations, appropriate cardiovascular risk assessments or screening programs for defined populations should be abandoned.

Nor do they invalidate health examinations required under Vietnamese law for particular workers or other regulated populations.

The relevant question is whether a specific assessment is likely to benefit the individual, considering age, symptoms, medical history, risk factors, available evidence and applicable clinical guidance.

For Lifestyle Medicine, prevention should be guided by clinical reasoning rather than by the number of tests included in a commercial package.

Why Extensive Wellness Testing Panels Require Caution

Laboratory testing is essential to modern healthcare.

Blood glucose and HbA1c measurements may be important when diagnosing or managing diabetes. Lipid testing can contribute to cardiovascular risk assessment in appropriate populations. Other investigations may be necessary because of symptoms, examination findings, medication use or existing medical conditions.

The concern arises when large numbers of tests are offered without a clear clinical question or evidence that the additional information will improve patient care.

A cross-sectional study published in Clinical Chemistry and Laboratory Medicine in 2026 examined commercial direct-to-consumer laboratory testing packages offered in the United States and Europe.[3]

The researchers evaluated 76 wellness panels from 12 platforms operating across seven countries. They identified 191 distinct laboratory tests, represented by 2,829 individual test instances across the packages.

The tests were classified into four categories according to their relationship with screening recommendations and their potential to contribute to low-value care or diagnostic cascades.

Of the 191 distinct tests, 58.1% were classified in the two categories associated with low-value testing or potential cascade-related harm in the screening context examined. Nine tests, predominantly certain tumor markers, were placed in the category associated with particular concern about diagnostic cascades.

These findings require careful interpretation.

The percentage refers to distinct tests classified using the researchers' framework. It does not mean that 58.1% of all laboratory tests are unnecessary, that the same proportion applies to every commercial package or that this percentage of patients experienced harm.

The classifications involved professional judgment, and agreement between the independent reviewers was below the study's prespecified target for its overall classification process.

Furthermore, the investigation examined commercial testing packages rather than directly measuring long-term patient outcomes.

The research did not assess Vietnamese laboratory providers. Its findings therefore cannot be presented as an estimate of inappropriate testing in Viet Nam.

Nevertheless, the study highlights a concern relevant whenever extensive testing is marketed to people without clear clinical indications.

A narrative review published in the Journal of General Internal Medicine in 2026 similarly examined the growing market for wellness investigations, including broad laboratory panels, direct-to-consumer genetic testing, wearable monitoring and whole-body imaging.[4]

The authors highlighted how commercial availability can outpace evidence that these investigations improve patient outcomes. They proposed a more selective approach to preventive assessment based on clinical risk and the ability to act meaningfully on results.

The proposed framework is a conceptual approach rather than a clinically validated solution for every healthcare setting. Its relevance lies in encouraging a more deliberate connection between testing and patient benefit.

Laboratory reference intervals generally describe values observed in defined reference populations. They are not always boundaries separating health from disease.

Some results outside a reference interval are clinically important. Others may reflect biological variation, measurement uncertainty, temporary physiological changes or factors unrelated to meaningful illness.

When numerous measurements are performed, the likelihood of finding at least one value outside a reference interval may increase, even in people without clinically important disease.

The significance of any finding depends on the investigation, the magnitude of the result, the patient's circumstances and the probability of the suspected condition before testing.

A large testing panel may appear comprehensive, but it can create uncertainty when information is collected without an appropriate clinical purpose or a clear plan for interpretation and follow-up.

Analytical Accuracy Is Not the Same as Clinical Usefulness

A laboratory test can measure a biological variable accurately without being useful for a particular clinical decision.

This distinction is essential when evaluating preventive biomarkers and wellness investigations.

Analytical validity concerns whether a test reliably measures its intended biological variable. Clinical validity concerns whether the result is meaningfully associated with a relevant medical condition, risk or outcome. Clinical utility concerns whether using that result improves clinical decisions or patient outcomes sufficiently to justify testing.

A biomarker may demonstrate a statistically significant association with disease risk while providing little useful information beyond established clinical assessment.

Likewise, a molecular measurement may be scientifically interesting without having a validated role in determining treatment for an otherwise healthy person.

A review published in Diagnostics in January 2026 examined the opportunities and risks associated with predictive biomarkers in asymptomatic adults.[5]

The authors discussed the expanding availability of molecular diagnostics, genetic profiling and commercial direct-to-consumer testing, emphasizing the importance of clinical validity, clinical utility and the risks of unnecessary follow-up.

These considerations are particularly relevant when biomarker results are used to recommend nutritional supplements, restrictive diets or other interventions marketed as personalized health optimization.

Before ordering a test, a healthcare professional should consider what clinical question it is expected to answer.

Would a positive result change management? Would a negative result provide meaningful reassurance? How would an uncertain or borderline finding be handled?

If none of the possible results would meaningfully alter appropriate care, the justification for testing may be weak.

If the result could influence management, the clinician must also consider whether the information is reliable, whether an effective intervention is available and whether acting on the finding is likely to benefit the patient.

The value of testing lies in its contribution to appropriate clinical decisions, not simply in the sophistication of the technology used.

Investigations That Require Particular Attention

Several categories of investigation illustrate why wellness testing should be evaluated according to the same standards applied to other clinical services.

Vitamin D Testing

Vitamin D assessment may be appropriate in selected circumstances, including certain bone disorders, malabsorption conditions or other situations in which the result can influence management.

However, routine population-based screening for vitamin D deficiency in otherwise low-risk, asymptomatic adults is not universally recommended.

Choosing Wisely Canada's pathology recommendations, updated in August 2026, advise against population-based screening for 25-hydroxyvitamin D deficiency.[6]

The recommendations recognize that testing may be appropriate for selected higher-risk patients when results will guide meaningful clinical decisions.

This is a Canadian professional recommendation, not a Vietnamese national guideline. Local assessment must consider the patient's actual condition, risk factors and applicable professional guidance.

The relevant principle is that testing should respond to a clinical need rather than the popularity of a biomarker in wellness marketing.

Food-Specific IgG Testing

Commercial food sensitivity panels sometimes measure immunoglobulin G responses to numerous foods and use the findings to recommend extensive dietary restrictions.

However, the Canadian Society of Allergy and Clinical Immunology, through Choosing Wisely Canada, advises against ordering food-specific IgG panels to diagnose food allergy or intolerance.[7]

Food-specific IgG generally reflects previous exposure to a food rather than establishing clinically important hypersensitivity.

Using such results to eliminate numerous foods can lead to unnecessary dietary restrictions, anxiety and potential nutritional problems.

This does not mean that suspected food allergy, intolerance or other diet-related conditions should be dismissed.

These concerns require appropriate clinical evaluation, with investigations selected according to the suspected condition rather than a broad commercial panel.

Commercial Gut Microbiome Testing

Research into the human gut microbiome has expanded considerably, and its potential clinical applications remain an important area of scientific investigation.

However, scientific progress does not automatically establish that a commercially available microbiome profile can reliably determine an individual's optimal diet, supplement requirements or medical treatment.

An international consensus statement published in The Lancet Gastroenterology & Hepatology in 2025 examined microbiome testing in clinical practice.[8]

The expert panel concluded that evidence supporting the clinical utility of many commercially available microbiome tests remains limited.

The statement also highlighted concerns about standardization, interpretation, reporting and the use of results in clinical management.

This does not diminish the importance of microbiome research. It means that research findings, commercially generated microbiome scores and validated clinical tests should not be treated as equivalent.

Broad Metabolic and Personalized Health Panels

Commercial wellness packages may include extensive measurements of hormones, micronutrients, metabolic markers and other biological variables.

Some components may be appropriate for selected patients. Their inclusion in a comprehensive package, however, does not establish that every investigation is necessary for everyone.

The same caution applies to emerging biological-age measurements, advanced molecular profiling and other personalized health investigations when their results are used to support clinical recommendations beyond the available evidence.

These examples are not intended to establish a list of tests that should never be performed.

Clinical appropriateness depends on the patient's condition, relevant indications, test performance, expected benefits and harms, and the decisions that the results are intended to inform.

When One Test Leads to Many Others

The consequences of unnecessary testing may extend beyond the initial investigation.

An unexpected result can lead to repeat laboratory testing, imaging, specialist referral or an invasive procedure. These steps may be necessary when a finding is clinically important, but they can also introduce additional risks, costs and uncertainty.

This sequence is often called a diagnostic cascade.

A cascade may begin with a false-positive result, an incidental finding of uncertain significance or an abnormality that does not require treatment.

The patient may undergo repeated assessments while clinicians attempt to determine whether the finding represents disease. Sometimes the process ends with reassurance that no treatment is needed. In other situations, further investigations reveal additional incidental abnormalities, creating another round of uncertainty.

Potential harms include procedural complications, radiation exposure where relevant, financial costs, time away from work and psychological distress.

Patients may also begin to consider themselves ill because of a result whose clinical importance remains unclear.

This does not mean that unexpected findings should be ignored. Once an investigation has been performed, its results require appropriate interpretation and follow-up according to their clinical significance.

The opportunity to prevent an unnecessary cascade often arises earlier, when the decision to order the initial test is made.

Avoiding unnecessary investigations is therefore a patient safety issue, not merely a strategy for reducing healthcare expenditure.

Lifestyle Interventions Must Also Demonstrate Value

Low-value care is not limited to laboratory investigations.

Interventions described as natural, preventive, personalized or lifestyle-based also require evidence of benefit and appropriate assessment of risk.

Programs involving extreme dietary restriction, prolonged fasting, unproven detoxification claims, high-dose supplementation or intensive exercise may be marketed as ways to improve metabolic health or prevent future illness.

The fact that an intervention involves food, exercise, supplements or ordinary biological processes does not establish that it is safe or effective.

A highly restrictive diet may create nutritional deficiencies or become difficult to sustain. Prolonged fasting may carry particular risks for people taking certain glucose-lowering medications or living with specific medical conditions. Some supplements may cause adverse effects, interact with prescribed treatment or expose patients to unnecessary expense.

An intensive exercise regimen may also be inappropriate for someone whose cardiovascular or functional condition requires individualized assessment.

The magnitude of these risks depends on the intervention and the patient's circumstances.

It would be equally incorrect to conclude that every supplement, dietary restriction or fasting intervention is ineffective.

Supplementation may be appropriate for identified deficiencies or specific medical indications. Therapeutic dietary approaches have established roles in selected clinical conditions. Certain forms of fasting are being investigated for particular outcomes.

The essential question is whether the proposed intervention is appropriate for the individual and supported by sufficiently reliable evidence.

An intervention should not be accepted merely because it is described as natural, traditional or innovative. Nor should it be rejected simply because it is new.

Clinical decisions should reflect the quality of evidence, the patient's needs and the expected balance of benefits and harms.

Evidence for Healthy Behaviors Is Not Evidence for Every Counseling Method

Avoiding low-value care also requires reflection on how Lifestyle Medicine recommendations are delivered.

A healthy behavior may be associated with better health without every method of promoting that behavior being equally effective.

Evidence that regular physical activity benefits health, for example, does not establish that a brief generic instruction to exercise will produce sustained behavior change in every patient.

Similarly, a scientifically sound dietary recommendation may be difficult to follow when an intervention does not address the person's resources, preferences and living circumstances.

This distinction was examined in a 2024 commentary published in Annals of Internal Medicine, which questioned whether clinical guidelines sufficiently distinguish evidence for the health benefits of lifestyle behaviors from evidence that clinician-delivered advice improves patient outcomes.[9]

The commentary prompted responses from other healthcare professionals, including representatives of the Lifestyle Medicine community, who emphasized the evidence supporting selected behavioral interventions and the importance of person-centered care.[10]

These publications represent a professional debate rather than a definitive conclusion that lifestyle counseling is ineffective.

The useful lesson is that evidence supporting a healthy behavior and evidence supporting a particular method of encouraging that behavior should be considered separately.

Effective Lifestyle Medicine services may require individualized counseling, collaborative goal-setting, appropriate follow-up and professional competencies in behavior change.

The amount and type of support should reflect the patient's needs and the intended outcome.

Repeated educational sessions may offer limited additional value when they reproduce information the patient already understands without addressing barriers preventing action.

Conversely, eliminating structured behavioral support solely to reduce costs may undermine care for people who genuinely need continuing assistance.

The objective is not to provide the greatest possible number of sessions or the fewest possible contacts. It is to provide appropriate, evidence-informed support that is proportionate to the patient's needs.

Scientific Uncertainty Must Be Communicated Clearly

An intervention may lack strong evidence because it is new, difficult to study or has received limited research funding.

The absence of high-quality evidence does not necessarily prove that the intervention is ineffective. However, it also does not justify presenting the intervention as clinically established.

When evidence is limited, healthcare professionals should explain the uncertainty and avoid making stronger claims than the research supports.

Patients should be able to distinguish between established care, promising approaches that remain under investigation and interventions for which meaningful evidence of benefit is unavailable.

A physiological mechanism can help generate a research hypothesis. It cannot replace evidence that the intervention improves outcomes in people.

Similarly, an association between a biomarker and disease does not automatically mean that changing the biomarker will improve health.

A commercial provider should not claim that an expensive program is effective merely because no study has conclusively disproved its benefits.

For Lifestyle Medicine, maintaining this distinction is especially important when discussing emerging approaches to personalized nutrition, preventive biomarkers and health optimization.

Scientific openness should be accompanied by appropriate restraint in clinical and commercial claims.

Shared Decision-Making When Patients Request More Testing

Patients may request investigations because they have read about a new biomarker, encountered promotional material or heard that comprehensive testing is essential for prevention.

These requests deserve a respectful response.

A person seeking more information about their health may be concerned about family history, worried about symptoms or genuinely interested in reducing future disease risk.

The clinician's responsibility is to understand the concern and explain which investigations are likely to help.

Simply dismissing a requested test without explanation may damage trust. However, agreeing to unnecessary testing solely to satisfy expectations may expose the patient to avoidable harm.

A useful conversation begins with what the patient hopes to learn.

The clinician can then explain what the proposed investigation measures, what different results may mean and whether the information is likely to influence clinical decisions.

Potential false-positive and false-negative findings, additional investigations and financial implications should also be discussed where relevant.

Sometimes the appropriate recommendation is a more focused assessment. In other circumstances, no additional testing may be necessary at that time.

Patients should understand the reasons for these recommendations and have opportunities to ask questions.

Respecting patient autonomy does not require offering every commercially available investigation. It requires clear information, meaningful participation in decisions and professional recommendations grounded in appropriate evidence.

Equally, clinically indicated screening or diagnostic assessment should not be delayed simply because an organization is seeking to reduce unnecessary testing.

Choosing not to investigate should be a reasoned clinical decision, not a blanket organizational restriction applied without considering individual circumstances.

Why Low-Value Care Persists in Healthcare Systems

Unnecessary investigations and interventions are sometimes attributed entirely to patient demand or individual clinical judgment.

In practice, the reasons are often more complex.

Healthcare organizations may promote broad testing packages because they are operationally convenient or financially attractive. Clinicians may request additional investigations because of concern about missing disease, limited access to decision support or expectations that comprehensive care should involve extensive testing.

Patients may also associate more testing with higher-quality healthcare.

Professional training, established routines and financial incentives can reinforce practices even when their value is uncertain.

A narrative review published in BMJ Open Quality in May 2026 examined initiatives addressing low-value care across six Asian countries: Japan, Singapore, South Korea, China, Malaysia and India.[11]

The authors reviewed 132 academic, policy and other sources and identified recurring factors involving healthcare financing, organizational arrangements, professional behavior and patient expectations.

They also found that systematic measurement of low-value care remained limited across the region.

The review did not include Viet Nam.

Its findings therefore offer useful regional context, but they do not establish the prevalence or specific causes of low-value care within Vietnamese healthcare.

For Viet Nam, the appropriate response is to investigate local practices rather than assume that findings from neighboring systems apply directly.

Reducing unnecessary care may require attention to how investigations are selected, how healthcare is financed, what patients expect and how organizations evaluate clinical appropriateness.

Professional education is important, but it may have limited impact when organizational processes continue to encourage unnecessary services.

De-Implementation: Improving Care by Reducing What Does Not Help

Healthcare improvement is often associated with introducing new technologies, services or clinical practices.

However, improving care may also require reducing, restricting, replacing or discontinuing activities that do not provide sufficient value.

This process is known as de-implementation.

De-implementation is not simply the reverse of introducing a new practice.

An established investigation or treatment may be embedded in clinical routines, electronic order sets, professional expectations and financial arrangements. Patients may also interpret the removal of a familiar service as a reduction in care quality.

A methodological paper published in Implementation Science Communications in June 2026 examined the distinct challenges involved in de-implementing low-value care.[12]

The authors discussed established habits, perceived loss, professional identity, organizational incentives and stakeholder expectations as factors that can make discontinuing existing practices difficult.

They emphasized the importance of defining what is being reduced or discontinued and why.

Different practices require different responses. Some investigations may need to be avoided when no appropriate indication exists. Others may remain useful but should be restricted to patients with specific risk factors. An established intervention may be replaced by a more evidence-supported alternative rather than simply discontinued.

The objective must remain clear.

A healthcare organization should not aim merely to reduce the total number of investigations performed. It should aim to reduce inappropriate testing while preserving access to services that provide meaningful clinical benefit.

Which Strategies Can Reduce Low-Value Care?

A systematic review and meta-analysis published in BMJ Medicine in September 2025 evaluated interventions intended to reduce low-value care in primary care.[13]

The review included 140 randomized controlled trials addressing unnecessary medicines, imaging, laboratory testing and other healthcare practices.

The authors found moderate-certainty evidence that clinician education combined with audit and feedback reduced targeted low-value care.

The pooled odds ratio was 0.73, with a 95% confidence interval from 0.63 to 0.84.

Other approaches, including clinician education alone, audit and feedback alone, patient education and combinations of strategies, showed possible benefits, although the certainty of evidence was generally lower.

An important limitation is that many trials focused on prescribing, particularly antibiotics. Their findings should not be assumed to apply with equal effectiveness to every category of wellness testing or commercial preventive healthcare.

Nevertheless, the review suggests that simply publishing a recommendation may not be sufficient to change established clinical practice.

Clinicians may benefit from reviewing their own ordering patterns, comparing them with appropriate clinical criteria and discussing the reasons behind variation.

Healthcare organizations may also need to revise electronic ordering systems, workflows or standard packages that encourage unnecessary investigations.

A scoping review published in Implementation Science Communications in December 2025 examined electronic health record interventions intended to reduce low-value care in primary care.[14]

The review identified approaches involving alerts, order sets, documentation templates and communication tools.

Results were mixed, and the authors identified limitations in the available evidence.

Electronic decision support may help clinicians make appropriate decisions, but poorly designed systems can create additional workload, alert fatigue or unintended barriers to necessary care.

A more useful approach combines clear clinical criteria, professional engagement, patient communication and ongoing evaluation.

For Vietnamese healthcare organizations, beginning with one clearly defined practice may be more practical than attempting to reform every aspect of preventive testing at once.

A Practical Quality Improvement Example in Viet Nam

Consider a hypothetical outpatient clinic that routinely offers an extensive wellness laboratory package to adults seeking preventive health consultations.

The package contains investigations that may be appropriate for selected patients but are not necessarily indicated for everyone.

The clinical team decides to evaluate whether the existing approach provides sufficient value.

The purpose is not to eliminate preventive assessment or reduce testing indiscriminately. It is to determine whether individual investigations have appropriate indications and whether the resulting information contributes meaningfully to patient care.

The team begins by reviewing applicable Vietnamese clinical guidance and relevant international evidence.

It distinguishes investigations that may be appropriate for defined populations from those requiring individualized risk assessment and those with uncertain value when used without a clear indication.

Clinicians then review appropriately protected patient records to understand why tests were ordered and what subsequent care resulted.

The assessment may identify investigations frequently ordered without a documented clinical purpose. It may also reveal patients whose risk factors were not adequately evaluated before testing decisions were made.

The clinic could then develop a more focused assessment process based on symptoms, medical history, relevant risk factors and clinical findings.

Patients would receive explanations about the investigations recommended and why certain tests may not provide additional benefit.

The team could monitor whether the revised process improves documentation and reduces inappropriate orders while preserving access to clinically indicated services.

Evaluation would also need to consider unintended consequences, including diagnostic delays, missed opportunities for appropriate screening, incomplete follow-up and patient dissatisfaction arising from inadequate communication.

A reduction in laboratory expenditure alone would not demonstrate success.

The project should aim to show that care became more appropriate without compromising patient safety.

This example is illustrative. It does not describe an existing VLMA quality improvement project, a validated Vietnamese protocol or a national recommendation concerning particular testing packages.

Any actual implementation would require appropriate professional involvement, institutional review and compliance with applicable healthcare requirements.

Clinical Governance Must Protect Against Underuse as Well as Overuse

Preventing low-value care requires balancing two responsibilities: reducing unnecessary activities and preserving access to effective healthcare.

An overly restrictive policy can create new risks.

A healthcare facility that discourages investigations without considering symptoms, risk factors or relevant guidelines may delay necessary diagnosis.

A clinician who becomes reluctant to refer patients because of pressure to reduce expenditure may expose them to preventable harm.

A decision-support system that blocks investigations indiscriminately may fail to accommodate important clinical exceptions.

For these reasons, decisions about reducing services should remain within appropriate clinical governance.

The organization should define the practice being reviewed, the evidence supporting its classification as low-value and the circumstances in which it remains appropriate.

Clinically justified exceptions should be recognized and documented.

Monitoring should consider not only service utilization and financial outcomes but also patient safety, diagnostic delays, clinical outcomes, equity and patient experience.

An investigation that provides little benefit for most people may remain essential for a smaller group with specific indications.

That group should not lose access because an organization adopts a broader initiative intended to reduce overuse.

The goal is to improve the appropriateness of care, not simply to reward lower service volume.

The Vietnamese Legal and Regulatory Context

Preventing low-value care in Viet Nam must operate within the country's healthcare regulatory framework.

The Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, provides the principal legal framework for regulated medical examination and treatment.[15]

The law addresses professional responsibilities, patient rights, healthcare quality and the lawful activities of healthcare facilities and practitioners.

Relevant implementing requirements include Government Decree No. 96/2023/NĐ-CP and Ministry of Health Circular No. 32/2023/TT-BYT, as subsequently amended, including by Circular No. 25/2026/TT-BYT.[16]

Circular No. 25/2026/TT-BYT, issued on June 30, 2026, amended selected provisions concerning laboratory quality management and other professional healthcare requirements. Its general effective date was August 15, 2026, while specified provisions took effect earlier.

These instruments are relevant when services involve medical examination, diagnostic testing, interpretation of clinical results, treatment decisions or other regulated healthcare activities.

Calling a service wellness assessment, metabolic optimization, personalized health or Lifestyle Medicine does not independently authorize activities regulated under Vietnamese law.

At the same time, legal authorization to provide an investigation does not establish that the investigation is clinically appropriate for every patient.

Legal compliance and clinical usefulness are related but separate considerations.

The Law on Disease Prevention No. 114/2025/QH15, effective July 1, 2026, provides an additional framework for disease prevention, risk-factor management and related health activities.[17]

Its provisions reinforce the importance of prevention but should not be interpreted as authorization for unrestricted screening or unsupported commercial claims.

Where screening programs, health examinations or preventive services are specifically required or authorized under Vietnamese regulations, those requirements must be distinguished from commercial wellness packages offered without a clear clinical indication.

Advertising and Commercial Claims

Public communication about healthcare services, nutritional supplements and preventive health programs is subject to applicable advertising requirements.

Law No. 75/2025/QH15, amending the Law on Advertising, took effect on January 1, 2026.[18]

Government Decree No. 342/2025/NĐ-CP, effective February 15, 2026, provides further implementing requirements.[19]

The applicable obligations depend on the nature of the product, service and advertising activity.

Healthcare providers should avoid creating the impression that a commercial wellness package is medically necessary, scientifically validated or proven to prevent disease when those claims are unsupported.

Scientific terminology, professional credentials, laboratory reports and patient testimonials should not be used to create misleading expectations about clinical effectiveness or regulatory recognition.

Nutritional supplements and other health-related products remain subject to their applicable legal classifications and requirements concerning safety, labeling, advertising and permissible claims.

A product being legally marketed does not, by itself, demonstrate that it is clinically necessary or effective for an individual patient.

Conversely, limited evidence for one advertised use does not automatically mean that every possible use of the product is unlawful.

Scientific assessment and legal classification require separate consideration.

Patient Information and Data Protection

Preventive health packages and personalized testing services may generate substantial amounts of personal health information.

This may include medical history, laboratory results, genetic information, biological measurements and other sensitive data.

The Law on Personal Data Protection No. 91/2025/QH15 and Government Decree No. 356/2025/NĐ-CP both took effect on January 1, 2026.[20,21]

Government Decree No. 102/2025/NĐ-CP, effective July 1, 2025, also establishes requirements concerning health data management within its applicable scope.[22]

Organizations must determine the lawful basis and purpose of processing, establish appropriate information-security measures and comply with requirements concerning collection, access, use, disclosure and retention.

Information obtained through clinical assessment should not automatically be reused for unrelated advertising, product promotion or commercial profiling.

Collecting additional biological information creates responsibilities beyond the immediate consultation.

The justification for an investigation should therefore consider not only whether the information may have clinical value but also whether collecting and processing it is necessary and proportionate.

Professional Independence and Conflicts of Interest

Low-value care can persist when commercial incentives influence how investigations and interventions are promoted.

A healthcare professional or organization may receive income from laboratory testing, supplements or wellness programs.

Such financial relationships do not automatically establish that the clinical advice is inappropriate.

However, they can create conflicts of interest that require transparency and appropriate management.

Clinical recommendations should be guided by patient needs and relevant evidence, not by the financial return associated with a particular investigation or product.

Patients should receive understandable information about the purpose, expected benefits, potential harms, uncertainties and reasonable alternatives before agreeing to an intervention.

Healthcare organizations should also distinguish professional education from commercial promotion.

A sponsored educational activity should not create the impression that a commercial product has received clinical endorsement from a professional organization without an appropriate basis.

For the Vietnam Lifestyle Medicine Alliance, maintaining scientific independence is essential to professional credibility.

An educational platform can discuss advances in laboratory medicine, nutrition science, preventive healthcare and emerging technologies without endorsing every product or service marketed within those fields.

Scientific uncertainty should remain visible even when an intervention is popular or commercially attractive.

The relevant question is not simply whether a service can be offered, but whether offering it is justified for the patient.

Building a Culture of Appropriate Care

Preventing low-value care is not an argument for providing less medicine in every situation. It is an argument for providing appropriate medicine.

Patients should receive evidence-based screening when indicated, timely assessment of concerning symptoms and access to treatments that offer meaningful benefit.

They should also be protected from unnecessary investigations, unsupported interventions and commercial claims that create unrealistic expectations.

Healthcare professionals need the confidence to explain why a test may not be necessary, just as they need the competence to recognize when further investigation is important.

Healthcare organizations need clinical governance arrangements that support appropriate decisions rather than rewarding service volume alone.

Professional education should strengthen critical appraisal, interpretation of test results, shared decision-making and recognition of potential harm.

Clinical teams should have opportunities to question established routines when their value is uncertain.

The process should remain respectful.

Patients requesting extensive testing may have understandable concerns. Clinicians ordering unnecessary investigations may be working within systems that encourage defensive practice or provide limited decision support.

Improvement is more likely when these underlying factors are addressed than when responsibility is assigned to individuals alone.

A culture of appropriate care allows patients and professionals to discuss uncertainty openly and make decisions according to evidence, clinical context and patient priorities.

Better Lifestyle Medicine Does Not Mean More Medicine

Lifestyle Medicine offers opportunities to improve prevention and chronic disease management through evidence-based therapeutic changes in everyday behavior.

Its contribution should not be measured by the number of biomarkers collected, supplements prescribed, testing packages sold or investigations performed.

A comprehensive assessment may be valuable when clinically indicated. A focused evaluation may be more useful when it addresses a clearly identified patient need.

Some people require detailed medical investigation before beginning or intensifying lifestyle interventions. Others may benefit from appropriate risk assessment, counseling and follow-up without an extensive laboratory package.

The difference depends on the patient's circumstances, not the marketing category of the service.

Recent research reinforces this approach.

Evidence on general health checks demonstrates that detecting more abnormalities does not necessarily translate into fewer deaths or cardiovascular events.

Research on commercial laboratory panels highlights uncertainty and the potential harms associated with broad testing in people without clear indications.

Studies of de-implementation show that reducing unnecessary care requires more than publishing recommendations. It involves clinical decision-making, organizational processes, patient communication and monitoring for unintended consequences.

For Vietnamese healthcare organizations, these findings support closer examination of how investigations and interventions are selected, explained and evaluated.

For the Vietnam Lifestyle Medicine Alliance, the subject is consistent with advancing evidence-based Lifestyle Medicine through professional education, scientific knowledge exchange and responsible implementation.

The objective is not to establish a list of prohibited tests, reject emerging scientific fields or discourage appropriate prevention.

It is to encourage healthcare professionals to distinguish established benefits from promising hypotheses, clinically useful information from unnecessary measurement, and legitimate preventive care from unsupported claims.

Good prevention is not defined by doing everything that is technically possible. It is defined by providing care that is appropriate, beneficial and safe for the person who needs it.

Preventing low-value care is therefore not separate from the development of evidence-based Lifestyle Medicine. It is an important part of making that development scientifically credible, clinically responsible and worthy of patient trust.

References and Further Reading
  1. Wang Y, Zhao Q, Zhu X, et al. Effectiveness and Cost-Effectiveness of General Health Checks in Adults: A Systematic Review. BMC Public Health. 2026;26:2720. doi:10.1186/s12889-026-28436-4.

  2. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General Health Checks in Adults for Reducing Morbidity and Mortality From Disease. Cochrane Database of Systematic Reviews. 2019;(1):CD009009. doi:10.1002/14651858.CD009009.pub3.

  3. Agrawal S, Rehan L, Mazur G, Chudek JT. Clinical Utility and Harm Potential of Direct-to-Consumer Laboratory Test Panels: A Cross-Sectional Content Analysis Across Commercial Providers in the United States and Europe. Clinical Chemistry and Laboratory Medicine. 2026;64(11):2419–2429. doi:10.1515/cclm-2026-0679.

  4. Ho ML, Topol EJ, Rajpurkar P. Critically Appraising the Wellness Movement: Cost Without Value, A Narrative Review. Journal of General Internal Medicine. 2026;41(5):1358–1366. doi:10.1007/s11606-025-10099-3.

  5. Wiedermann CJ, Piccoliori G, Engl A, Hager von Strobele-Prainsack D. Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice. Diagnostics. 2026;16(2):196. doi:10.3390/diagnostics16020196.

  6. Choosing Wisely Canada. Pathology: Tests and Treatments to Question. Canadian Association of Pathologists. Updated August 2026.

  7. Choosing Wisely Canada. Allergy & Clinical Immunology: Tests and Treatments to Question. Canadian Society of Allergy and Clinical Immunology. Updated May 2025.

  8. Porcari S, Mullish BH, Asnicar F, et al. International Consensus Statement on Microbiome Testing in Clinical Practice. The Lancet Gastroenterology & Hepatology. 2025;10(2):154–167. doi:10.1016/S2468-1253(24)00311-X.

  9. Johansson M, Niklasson A, Albarqouni L, Jørgensen KJ, Guyatt G, Montori VM. Guidelines Recommending That Clinicians Advise Patients on Lifestyle Changes: A Popular but Questionable Approach to Improve Public Health. Annals of Internal Medicine. 2024;177(10):1425–1427. doi:10.7326/ANNALS-24-00283.

  10. Rosenfeld RM. Guidelines Recommending That Clinicians Advise Patients on Lifestyle Changes. Annals of Internal Medicine. 2025;178(8):1213–1214. doi:10.7326/ANNALS-25-01850.

  11. Yeo JX, Tokuda Y, Sasaki S, et al. Addressing Low-Value Care (LVC) in Asia: A Narrative Review of Choosing Wisely and Other Initiatives Across Asia. BMJ Open Quality. 2026;15:e003806. doi:10.1136/bmjoq-2025-003806.

  12. Sergerie-Richard S, Fontaine G, Goulet MH. De-Implementation of Low-Value Care: Contrasting Theories, Models, and Frameworks to Generate Methodological Guidance. Implementation Science Communications. 2026;7:158. doi:10.1186/s43058-026-01007-9.

  13. Raudasoja A, Parpia S, Mustonen JMJ, et al. Effectiveness of Different De-Implementation Strategies in Primary Care: Systematic Review and Meta-Analysis. BMJ Medicine. 2025;4:e001343. doi:10.1136/bmjmed-2025-001343.

  14. Nguyen OT, Vo SD, Nguyen D, et al. The Role of Electronic Health Record Systems in De-Implementing Low-Value Care in Primary Care: A Scoping Review. Implementation Science Communications. 2025;6:138. doi:10.1186/s43058-025-00826-6.

  15. National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, January 9, 2023, as amended. Office of the National Assembly, Consolidated Document No. 26/VBHN-VPQH, February 26, 2026.

  16. Government of Viet Nam. Decree No. 96/2023/NĐ-CP, December 30, 2023, Detailing Selected Provisions of the Law on Medical Examination and Treatment, as applicable. Ministry of Health. Circular No. 32/2023/TT-BYT, December 31, 2023, as subsequently amended, including by Circular No. 25/2026/TT-BYT, June 30, 2026.

  17. National Assembly of Viet Nam. Law on Disease Prevention No. 114/2025/QH15, December 10, 2025. Effective July 1, 2026.

  18. National Assembly of Viet Nam. Law No. 75/2025/QH15, June 16, 2025, Amending and Supplementing the Law on Advertising. Effective January 1, 2026.

  19. Government of Viet Nam. Decree No. 342/2025/NĐ-CP, December 26, 2025, Detailing Selected Provisions of the Law on Advertising. Effective February 15, 2026.

  20. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15, June 26, 2025. Effective January 1, 2026.

  21. Government of Viet Nam. Decree No. 356/2025/NĐ-CP, December 31, 2025, Detailing Selected Provisions and Implementation Measures of the Law on Personal Data Protection. Effective January 1, 2026.

  22. Government of Viet Nam. Decree No. 102/2025/NĐ-CP, May 13, 2025, on Health Data Management. Effective July 1, 2025.

Editorial, Clinical and Regulatory Note

This article is published by the Vietnam Lifestyle Medicine Alliance (VLMA) for professional education, scientific knowledge exchange and discussion of responsible approaches to preventing low-value care within evidence-based Lifestyle Medicine in Viet Nam.

It provides an educational review of selected international research, clinical quality principles and Vietnamese regulatory considerations. It is not a Vietnamese national clinical guideline, an official list of unnecessary investigations, an approved treatment protocol, a professional licensing standard, a healthcare reimbursement determination or an authoritative legal opinion.

The concepts of low-value care, overuse, overdiagnosis, overtreatment and de-implementation are discussed to explain their scientific and clinical significance. They should not be interpreted as establishing that every investigation or intervention mentioned is inappropriate in all circumstances.

The appropriateness of a test or intervention depends on the patient's condition, relevant risk factors, clinical indication, test performance, available evidence, expected benefits and harms, and applicable professional guidance.

International professional recommendations, including those issued through Choosing Wisely, do not automatically constitute Vietnamese national clinical standards.

Healthcare professionals should not delay or withhold clinically indicated screening, diagnostic assessment, treatment, medication monitoring or specialist referral merely because an activity has been discussed in the context of low-value care.

Hypothetical quality improvement examples are illustrative. They are not presented as approved Vietnamese clinical protocols or projects already implemented by VLMA.

Any regulated medical examination, diagnostic testing, treatment or related healthcare service must comply with applicable Vietnamese legislation, professional requirements, healthcare facility authorizations and patient safety obligations.

Health-related advertising, commercial product claims, personal-data processing and research activities must comply with the regulatory and institutional requirements applicable to their actual nature.

VLMA does not independently authorize clinical services, issue medical practice licenses, certify diagnostic tests for regulatory purposes, approve treatment protocols or endorse particular commercial laboratories, products or service providers through this article.

The scientific and regulatory materials referenced were reviewed through November 22, 2026. Healthcare organizations considering clinical implementation or formal quality improvement activities should verify the currently applicable requirements and obtain appropriate professional and institutional review.

Vietnam Lifestyle Medicine Alliance

Evidence-Based Lifestyle Medicine for Viet Nam.

Contact

contact@vlma.org

Saigon Paragon Building, No. 3 Nguyen Luong Bang Street, Tan My Ward, HCMC

+84 909 228 476

+84 84 9999 911

© 2025 - 2026. Vietnam Lifestyle Medicine Alliance. All rights reserved.

A physician-led professional platform advancing Lifestyle Medicine through education, collaboration, research, and responsible implementation.

VLMA is operated by Vietnam Lifestyle Medicine Alliance Company Limited, Enterprise Registration Number 0318902666.

VLMA is a Sister Organization of the Lifestyle Medicine Global Alliance and a Member Organization of the Planetary Health Alliance.

VLMA is not a medical service provider and does not issue medical licenses or IBLM certification.